ArticleFrontiers in oncology2022

Urethra Sparing With Target Motion Mitigation in Dose-Escalated Extreme Hypofractionated Prostate Cancer Radiotherapy: 7-Year Results From a Phase II Study.

Carlo Greco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.